Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Multi-national, Multi-centre, Open Label, Safety Study to Assess the Safety of Chronic Therapy With the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed 4-weekly), in the Treatment of Patients With Active Crohn's Disease Who Have Previously Completed Studies CDP870-031 or CDP870-032

NCT00160524 is registered in ClinicalTrials.gov with UCB Pharma SA as lead sponsor.

NCT NCT00160524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00160524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Multi-national, Multi-centre, Open Label, Safety Study to Assess the Safety of Chronic Therapy With the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed 4-weekly), in the Treatment of Patients With Active Crohn's Disease Who Have Previously Completed Studies CDP870-031 or CDP870-032
Lead sponsor
UCB Pharma SA
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2004
Completion date
August 31, 2012
Enrollment
596 (actual)
Sites
206

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease